Experience

Gabaeron
• United States
• Biotechnology Research
• 1 - 100 Employee
• Research Scientist II

  • Feb 2022 - Present


Eureka Therapeutics, Inc

• United States
• Biotechnology Research
• 1 - 100 Employee

• Clinical Specialist

  • Aug 2021 - Feb 2022

• Associate Research Scientist II

  • Jan 2020 - Sep 2021

  Collaborated with other scientists with ARTEMIS® platform optimization by performing upstream and downstream assays, pushing our IND filing forward; Lead in a challenge project from experiment design, the pilot assay, and data analysis.

• Research Specialist

  • May 2018 - Dec 2019

  Dedicated in TCR based platform optimization: Produced several hundred of high quality lentivirus, organized stocks and made an easy-to-use inventory; In charge of T cell production and QC process for research purpose; Cancer cell lines maintenance and cell banking. Trained 2 new employees and mentored 1 intern on virus production, cell culture, and FACS technology.



The J. David Gladstone Institutes

• Postdoctoral Fellow

  • Feb 2012 - Dec 2015

  Working on cell reprogramming and cell differentiation related with Coronary Artery Disease. Combined with chemical screening, I developed and optimized the reprogramming system and get patient-specific iPS cells done from 70 PBMC samples. I also worked on high-throughput chemical screening for YAP inhibitors. From about 30,000 compounds, 120 hits have been discovered in the primary screening and confirmed by the secondary assay in vitro. Working on cell reprogramming and cell differentiation related with Coronary Artery Disease. Combined with chemical screening, I developed and optimized the reprogramming system and get patient-specific iPS cells done from 70 PBMC samples. I also worked on high-throughput chemical screening for YAP inhibitors. From about 30,000 compounds, 120 hits have been discovered in the primary screening and confirmed by the secondary assay in vitro.